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This sixth best practice review examines four series of common
primary care questions in laboratory medicine: (1) laboratory
monitoring in hypertension and heart failure abnormalities; (2)
markers of inflammatory joint disease; (3) laboratory
investigation of chronic diarrhoea; and (4) mumps and
chickenpox. The review is presented in question–answer format,
referenced for each question series. The recommendations
represent a precis of guidance found using a standardised
literature search of national and international guidance notes,
consensus statements, health policy documents and evidence-
based medicine reviews, supplemented by Medline Embase
searches to identify relevant primary research documents. They
are not standards but form a guide to be set in the clinical
context. Most are consensus based rather than evidence based.
They will be updated periodically to take account of new
information.
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T
his is the sixth in a planned series of reviews to
answer a number of questions that arise in
primary care use of pathology.
Each topic is introduced with a brief summary of
the type of information found, followed by the
related questions and answers, with main recom-
mendations listed as bullet points accompanied by
a justification.
Although the individual topics are not related as
they cover the disciplines of clinical biochemistry,
microbiology, immunology, haematology and cel-
lular pathology, they are designed, once com-
pleted, to form a resource that will be indexed and
cover a wide range of the most common primary
care laboratory issues, to be made available to
users.
In instances where the new UK General Medical
Services (GMS) contracts make specific reference
to a laboratory test, the indicator or target is
appended at the end of the answer.
RENAL FUNCTION AND ELECTROLYTE
MONITORING IN PATIENTS RECEIVING
DIURETICS, ANGIOTENSIN-CONVERTING
ENZYME INHIBITORS OR ANGIOTENSIN II
RECEPTOR ANTAGONISTS IN PRIMARY
CARE (JJC, TMR, WSAS)
These questions cover a wide range of clinical
scenarios in primary care, and are written to guide
the monitoring of ambulatory patients only out-
side the acute setting. As the diagnoses of
hypertension and heart failure group together a
wide range of clinical and biochemical scenarios, it
is not possible to produce guidance that covers
every situation, although the published recom-
mendations available concur on most general
principles. These answers should therefore be
interpreted as principles to guide monitoring in
such patients.
References to nephrology advice in these
answers requires further work to establish actions
to take in such patients, as it is probably not
practical or even desirable for all patients with
raised serum creatinine (.200 mmol/l or estimated
glomerular filtration rate (eGFR) ,30 ml/min) to
be referred to nephrology services. Further gui-
dance needs to be developed for these situations,
and the thresholds cited are intended as limits
where further advice is recommended before
initiating or continuing the treatments described.
Another difficulty that monitoring introduces in
primary care is the production of reliable potas-
sium results in practices served by a distant
specimen collection service, when sample dete-
rioration may adversely affect, particularly potas-
sium, results. This is a topic that merits further
examination in the context of primary care
monitoring.
Drugs are treated broadly by class, which does
not take account of possible intraclass specificities.
In instances where reference is made to spirono-
lactone, it would seem reasonable to extrapolate to
eplerenone, pending future guidance.
Higher-risk patients include those with existing
renal dysfunction(eg, stage 3 chronic kidney
disease), patients aged >60 years, those receiving
combination therapy (eg, angiotensin-converting
enzyme inhibitors (ACEI)/diuretics or potassium-
sparing drugs) and those with relevant concomi-
tant disease such as peripheral vascular disease,
diabetes.
How often should renal function (creatinine,
and electrolytes) be monitored in patients
with heart failure receiving diuretics, ACEI or
angiotensin II receptor antagonists?
We recommend:
N before initiating treatment
N 1–2 weeks after each dose increase/relevant
drug addition in low-risk patients
Abbreviations: ACEI, angiotensin-converting enzyme
inhibitors; ARB, angiotensin II receptor antagonists; CRP, C
reactive protein; eGFR, estimated glomerular filtration rate;
ESR, erythrocyte sedimentation rate; FBC, full blood count;
GFR, glomerular filtration rate; GMS, General Medical
Services; HLA, human leucocyte antigen; RhF, rheumatoid
factor; SpA, spondyloarthritides; VZIG, varicella-zoster
immunoglobulin; VZV, varicella-zoster virus
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N 5–7 days in higher-risk patients (eg, those receiving spir-
onolactone, those with existing renal dysfunction, those
receiving combination therapy or any of the above)
N during intercurrent illness
N remeasuring within 2 weeks if serum creatinine rises .20%
or eGFR falls .15%1
N during chronic treatment, every 3–6 months in stable
higher-risk patients up to annually in stable lower-risk
patients.1
Many drug classes are used in the treatment of heart failure.
Guidance for ACEI and angiotensin II receptor antagonists
(ARBs) is given in Veterans Health Administration DoVA.2
Glomerular filtration falls in patients receiving these drugs. In
addition, hypokalaemia may occur with both thiazide and loop
diuretics, and hyperkalaemia with potassium-sparing diuretics
(triamterene, amiloride and spironolactone), an ACEI or ARB.
Electrolytes should be measured more often if the patient is
receiving both diuretics and digoxin, or if they become
hypokalaemic or hyperkalaemic.2 A compromise may be
required between peripheral oedema and acceptable serum
electrolyte and renal function results, with lower doses in
patients with reduced glomerular filtration rate (GFR).
With potassium-sparing diuretics, notably spironolactone or
eplerenone in the context of heart failure, the European
Taskforce guidelines recommend that serum potassium and
creatinine should be checked after 5–7 days and the dose
titrated accordingly, and that values should be rechecked every
5–7 days until the potassium values are stable.3 The Renal
Association guideline1 refers to 1–2 weeks in the context of
ACEI or ARB. This patient group represents a continuum for
low to higher risk depending on age, renal function and drugs
used, and the retest interval reflects this within the general
guideline of 5–14 days. Practitioners should be aware that
because of method differences, creatinine and eGFR results
from different laboratories may not be reproducible and should
make themselves aware of result differences if more than one
source of testing is used (eg, two laboratories or points of care
testing).
This guidance refers specifically to clinically stable patients in
primary care as inpatients are, by definition, potentially
unstable and will usually require more frequent monitoring of
renal function. It is recommended that the serum electrolytes
and renal function be checked every 1–2 days, according to the
diuretic response in acute circumstances4 or if admitted to
hospital.
Diuretics are often prescribed in increasing doses, and
combinations of diuretic classes are also used. Combinations
of thiazide and loop diuretics can cause a powerful diuresis in
patients with previously diuretic-resistant oedema. Patients are
often initiated on this combination treatment in hospital and
will therefore have more frequent monitoring. Patients out of
hospital should remain under close clinical supervision, and
may receive combination treatment on a once-weekly or twice-
weekly basis initially.5 These patients are at higher risk of
worsening renal function and hyponatraemia and should have
their renal function checked 5–7 days after starting this
combination or increasing doses within the combination
treatment, and thereafter at a retest interval of 5–14 days
depending on stability. Combination treatment also requires
monitoring of weight and hydration status, and evidence of too
rapid a diuresis or dehydration should prompt earlier testing.
Most guidance refers to serum creatinine and/or eGFR as the
renal indicators, although many practitioners will use serum
urea as an additional indicator of hydration status.
Diuretics should be used in the lowest possible doses to
control symptoms of fluid overload,6 but patients often run into
problems with deteriorating renal function or deranged
electrolytes at these doses. Renal function should be checked
before initiating treatment and 1–2 weeks after each dose
increment.1 3 6
Spironolactone (low dose) has been shown in the
Randomized Aldactone Evaluation Study to reduce morbidity
and mortality in patients with heart failure.7 Electrolytes should
be monitored to avoid dangerous hyperkalaemia (see question
below for guidance).3 Patients shown to benefit from this
treatment were those with severe heart failure (New York Heart
Association classes 3 or 4) who are likely to be under hospital
follow-up and/or shared care. Studies since the publication of
the Randomized Aldactone Evaluation Study have shown that
cohorts of patients treated with spironolactone for heart failure
have shown higher rates of hyperkalaemia than those in the
original trial.8 Following the trial protocol, the monitoring of
electrolytes was performed within a week of starting treatment,
at 4, 8 and 12 weeks, and then every 3 months during
treatment if stable. In view of more recent evidence, however,
it is recommended that spironolactone (or other agents with
potassium-sparing properties, eg, amiloride and triamterene)
be introduced at a low dose for 1 week, with a check of serum
potassium and creatinine after 5–7 days, with titration of the
drug as necessary.3 The blood tests should be rechecked every
5–7 days until the potassium values are stable.3
Existing guidelines concur that serum creatinine and
electrolytes should be measured at 5–14 days after initiating
treatment with an ACEI or ARB and 1–2 weeks after any dose
increase.1 9 Thereafter, during chronic treatment serum creati-
nine and electrolytes should be checked between every 3–
6 months afterwards,6 up to annually, depending on renal
function.
How often should renal function tests be monitored in
patients with hypertension receiving, ACEI or ARB?
We recommend:
N Before initiating treatment.
N 1 week after starting treatment or any subsequent dose
increase.10
N At 4 and 10 days after starting treatment or increase in dose
in patients at higher risk of developing hyperkalaemia or
deteriorating renal function (eg, peripheral vascular disease,
diabetes mellitus, pre-existing renal impairment and older
patients).11
Consider seeking further advice if a patient has:
N Renal impairment (serum creatinine .200 mmol/l or eGFR
,30 ml/min) or confirmed/suspected renovascular disease
before initiating ACEI/ARB.12
N Marked creatinine rise (>30%) with large fall in blood
pressure after starting ACEII or ARB may suggest renovas-
cular disease that should be investigated.13
The major risks of using an ACEI/ARB are of hyperkalaemia
or deterioration of renal function. The general consensus is that
serum creatinine and electrolytes should be measured 1 week
after initiating treatment with an ACEI or ARB and 1 week
after any dose increase.10 A limited elevation in serum
creatinine (ie, (30% above baseline) is a common occurrence
in patients after the initiation of ACEI or ARB, and if it occurs
will happen within the first 2 weeks of treatment.14 During
chronic treatment, repeated measurements should be initiated
only if the patient’s clinical condition worsens or additional
treatment is started, else it is considered best to repeat renal
function and electrolytes every 3–6 months.
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Patients with hypertension with raised serum creatinine
(serum creatinine .200 mmol/l) before starting treatment may
have renovascular disease, intrinsic renal disease or obstructive
uropathy, and therefore should be referred for specialist
evaluation before receiving either diuretic or ACEI or ARB
treatment.12 Referral is also recommended if the serum
creatinine rises >30% are associated with a large reduction in
the blood pressure after initiating treatment with ACEI or ARB,
as this may suggest renovascular disease.13 Caution is required
if the serum creatinine is .150 mmol/l, although in many
patients with intrinsic renal impairment the creatinine will not
increase further and may fall with treatment.10
Patients with hypertension are often treated with ACEI or
ARB, but many patients are also receiving other drugs, and
commonly >3 agents are needed to control blood pressure. In
difficult hypertension, there is an increasing vogue to use
different approaches including a combination of ACEI and
ARB, or the addition of spironolactone. These approaches may
increase the frequency of monitoring necessary, as early and
potentially more serious changes in renal function tests may
occur.
How often should electrolytes/renal function tests be
measured in patients with hypertension receiving
diuretics?
We recommend:
Thiazide or loop diuretics
N within 4–6 weeks of starting low-dose thiazide diuretic
treatment10 or loop diuretic treatment
N thereafter, in all patients every 6–12 months15
N or if a person’s clinical condition changes or a potentially
interacting drug is added.
Spironolactone or potassium-sparing diuretics
N before initiation of treatment (it should not be initiated if
the potassium values .5 mmol/l)
N after 5–7 days with dose titration if required
N every 5–7 days until the potassium values are stable
N 1–2 times/year up to every 4–8 weeks during chronic
treatment, depending on risk factors (older patients, renal
or cardiac dysfunction).
If potassium rises to .6 mmol/l, spironolactone or potas-
sium-sparing diuretics should be stopped and specialist advice
sought. Concomitant use of potassium sparing diuretics and
ACEI or ARB should normally be reserved for practitioners
experienced in such combinations and with increased monitor-
ing as for high-risk patients.
All classes of diuretics are used to treat patients with
hypertension. Thiazide diuretics (eg, bendroflumethiazide) are
more likely to cause hyponatraemia compared with the other
classes. This adverse effect seems to be more common in elderly
people.16 Thiazides may also cause hypokalaemia with the risk
of increasing arrythmias, and it is therefore recommended that
electrolytes be checked after 4–6 weeks of initiation of
treatment to monitor for these effects.10 It is logical to recheck
electrolytes and renal function if a person’s clinical condition
changes; lethargy, dizziness or vomiting for example may
indicate the development of hyponatraemia. The addition of
any treatment that may potentiate the adverse metabolic effects
of diuretics should also prompt rechecking of electrolytes and
renal function. Thereafter, during stable chronic treatment,
renal function and electrolytes should be measured every 6–
12 months,15 especially as adverse effects such as diuretic-
induced hyponatraemia may be insidious and appear even after
prolonged treatment.
Loop diuretics are associated with hypokalaemia and impaired
renal function (via pre-renal mechanisms) because of their
potent diuretic effect. Loop diuretics are used less commonly in
hypertension than thiazides, and are generally reserved for
patients with coexistent heart failure or renal impairment. The
monitoring requirements for loop diuretics are less clear, but we
believe it is reasonable to recommend the same guidance as for
patients given loop diuretics for heart failure.
Aldosterone antagonists and potassium-sparing diuretics (eg,
spironolactone, amiloride) are increasingly used for primary
hypertension in addition to their previous use in specific causes
of secondary hypertension. Use of these agents, often added to
ACEI or ARB, changes the frequency of creatinine/electrolyte
monitoring necessary and can cause severe hyperkalaemia.
Specialist guidance should be considered before using such
combinations (in our opinion). Hyperkalaemia is asymptomatic
and dangerous, therefore close observation is the only way of
avoiding the potential harms of treatment. Guidance on testing
intervals is limited; the American Joint National Committee17
recommends potassium measurement 1–2 times/year in all
patients treated with diuretics, not separating by class. Pending
more specific guidance, we therefore recommend that monitor-
ing should range from at least 1–2/per year in lower-risk
patients (no renal or myocardial dysfunction) to every 4–
8 weeks in higher-risk patients, in keeping with guidelines on
heart failure.
What level of rise in creatinine/electrolytes is
acceptable when a patient starts receiving a diuretic or
ACEI/ARB in heart failure or hypertension?
Creatinine
We recommend that:
N up to a 50% rise in serum creatinine from baseline may
represent a physiological response
N a creatinine rise of ,30% would not normally require action
N a creatinine rise of 30–50% (or to .200 mmol/l/eGFR
,30 ml/min) should prompt clinical review of volume
status, and temporary dose reduction or withdrawal of
diuretics (if hypovolaemic) or of the ACEI/ARB18
N a rise of .50% or to .256 mmol/l (eGFR approxinmately 20–
25 ml/min) should normally prompt dose reduction or
withdrawal of diuretic (if hypokalaemic) and/or stopping
ACEI/ARB pending further investigation or referral for
concurrent treatment with diuretic and ACEI/ARB; the
ACEI/ARB can be restarted if renal insufficiency improves
after reduction or withdrawal of diuretic.19
We recommend the same retesting intervals (ie, 5–7 days
until stable) as when initiating treatment and the same
threshold (,30% rise) for considering reintroduction.
If the potassium (K+) concentration is .5 mmol/l before
treatment, treatment with any drug that may increase the
serum potassium should normally only be initiated with
specialist advice.
Stable K+ increases to (6 mmol/l do not usually require
change in treatment, although:
N rises to 5.5–5.9 mmol/l should prompt more frequent
monitoring
N if it rises .6 mmol/l, all drugs that may increase potassium
and concomitant nephrotoxic drugs should be stopped and
specialist advice sought.1 20
Nephrology advice is recommended when:
N there is uncertainty about impaired or deteriorating renal
function6 especially if creatinine increases 50% above baseline14
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N the eGFR is ,30 ml/min
N the serum sodium falls to ,132 mmol/l (persistent after
water restriction if clinically applicable)6
N any serious hyperkalaemia (K+.6 mmol/l) develops on
treatment
N strong clinical grounds exist for continued drug use in the
presence of rising potassium to levels requiring dose
reduction.
BACKGROUND
A rise in urea and creatinine is expected when a patient starts
receiving ACEI because of a complex interaction of the renin–
angiotensin–aldosterone system and renal vasculature. This
interaction can lead to a decrease in the GFR and an impaired
potassium excretion in some patients. Diuretics likewise affect
kidney function via an intrinsic renal feedback mechanism and
can lead to renal impairment in some individuals. Diuretics are
best used flexibly and in the minimum dose to reduce
symptoms and maintain ‘‘dry weight’’ to avoid electrolyte
disturbances.6 In addition, it is advised that, to avoid renal
insufficiency when the degree of diuresis exceeds the mobilisa-
tion of fluid in patients with oedema with heart failure or
hypertension, the dose of diuretic is adjusted so that the
patient’s weight reduction does not exceed 1 kg/day.21
Deterioration in renal function in patients with hypertension
or heart failure is often seen when either ACEI or ARB are used.
In both cases, this represents a change in the effective arterial
volume when the drugs are started. In most cases, a mild rise
(up to 30% above baseline) will not require action. Any
increases beyond this level may represent volume depletion
either from overaggressive diuresis, low cardiac output—more
common in patients with heart failure or bilateral renal artery
stenosis—seen potentially in both hypertension and heart
failure, when large falls in GFR may occur in the presence of
maintained blood pressure. It is therefore advisable in these
instances to review volume status. If the patient is found to be
volume depleted and the patient is treated with diuretic and
ACE I/ARB combination, the diuretic should be withheld before
reducing or withholding the ACEI/ARB.6 22
If the patient is not hypovolaemic and both diuretic and
ACEI/ARB are stopped or reduced, we recommend the same
retesting intervals (ie, 5–7 days until stable) as when initiating
treatment and the same threshold (,30% rise) for considering
reintroduction, although we found no specific guidance on this
topic.
In all cases of long-term deterioration in renal function, other
causes of renal deterioration such as diuretic-related volume
depletion, other drug effects, notably non-steroidal anti-
inflammatory drugs, or other renal disease should be con-
sidered.23
Other guidelines relating to treatment for hypertension state
that ‘‘A limited increase in serum creatinine of as much as 35%
above baseline with ACEI/ARB is acceptable and not a reason to
withhold treatment unless hyperkalaemia develops’’.24 If
patients are receiving a high dose of an ACEI and not volume
depleted, many clinicians will reduce the dose of the ACEI if the
creatinine rises 30–50% above baseline rather than stop it
altogether. The European Society for Cardiology25 consensus
document recommends stopping ACEI (and by extrapolation
ARB) if the serum creatinine rises to .50% or to .256 mmol/l.
Patients with hypertension with coexistent peripheral vas-
cular disease, suspicion of renal artery atherosclerosis or clinical
evidence of vascular/renal bruits should be referred for
specialist evaluation before starting ACEI or ARB in view of
the risk of renal artery stenosis and its related deterioration in
renal perfusion after initiating treatment.13
Referral is recommended if there is existing renal impair-
ment, especially if there is uncertainty about the diagnosis or
the cause of deterioration in renal function.6 As management
discussion with a nephrologist is recommended for patients
with stage 4 chronic kidney disease (GFR ,30 ml/min),1
decisions on ACEI/ARB treatment should flow from this
discussion.
The use of an ARB in patients previously intolerant of an
ACEI (because of hypotension, hyperkalaemia or renal dys-
function) need to be more carefully monitored during treat-
ment and any subsequent dose titration. Recently, the use of a
combination of ACEI and ARB has been trialled more so in
heart failure26; this approach will usually be under specialist
care and again will require more careful monitoring of blood
chemistry than the recommendations given.
Hyperkalaemia is asymptomatic and potentially dangerous.
Patients will often become hyperkalaemic while on treatment
with ACI inhibitors/ARB or with diuretics that ‘‘spare’’
potassium (eg, amiloride, spironolactone); this adverse effect
is potentiated by any degree of renal impairment. Many other
factors may increase the risk of hyperkalaemia, including the
use of non-steroidal anti-inflammatory drugs, heparin or
b-blockers; the presence of diabetes mellitus; advancing age;
concurrent illnesses especially with dehydration; and the use of
‘‘low-salt’’ substitutes. The potassium level is usually measured
before any drugs are given that could potentially increase the
level. Caution is recommended when prescribing these drugs if
the serum potassium is .5 mmol/l, and we suggest that
specialist advice be sought in these cases to reduce risk to
patients. A subsequent rise in the potassium level is likely, and
monitoring is important until the level has reached a plateau. A
rise to .6 mmol/l necessitates stopping all drugs that that may
increase potassium1 and concomitant nephrotoxic drugs;
specialist advice should be sought.19
GMS contract indicator: none specific to these situations,
although indicators have been introduced for chronic kidney
disease.
RHEUMATOID FACTOR AND HUMAN LEUCOCYTE
ANTIGEN B27 IN THE INVESTIGATION OF
INFLAMMATORY JOINT PAIN (PCD, RH, WSAS, GPS)
These questions consider two common clinical scenarios in
primary care: diagnosis and monitoring of rheumatoid disease
in small joint pain (PCD and RH), and the utility of the human
leucocyte antigen (HLA) B27 in the investigation of low back
pain (WSAS and GPS). They highlight the limitations of both
these tests as diagnostic markers, and the need for a clinical
filter designed to distinguish inflammatory from other mechan-
ical joint pain before further investigation. In particular, they
also show that repeat measurement of RhF seems to have no
role in patients with rheumatoid arthritis.
What information does rheumatoid factor (RhF)
measurement provide in the investigation of multiple
small joint diseases and in whom should I measure it?
We recommend measurement of RhF:
N only in patients with evidence of inflammatory arthropathy
(raised erythrocyte sedimentation rate (ESR) or C reactive
protein (CRP), joint swelling or damage)
N as part of the diagnosis of rheumatoid disease, for diagnostic
and prognostic purposes.
Rheumatoid factor (RhF) can be measured by a number of
differing assays, with variation in quantitation, sensitivity and
specificity.
The type of assay used will determine its usefulness.
Agglutination assays are less sensitive and are mainly used
228 Smellie, Forth, Coleman, et al
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for screening purposes. Nephelometric assays and ELISA are
more sensitive and provide a quantitative measure of RhF. Your
local laboratory will be able to provide further information on
the assay used.
There is agreement that although RhF is present in 70–90% of
patients with rheumatoid arthritis, its absence does not exclude
rheumatoid arthritis although these patients have a milder
disease.27–29
A positive RhF at low titre is found in a variety of diseases,
particularly immunological disorders, infectious diseases and
haematological malignancies.27–29
RhF is used as a criterion in the American Rheumatism
Association guidelines for the diagnosis of rheumatoid arthritis,
but the assay variability means that there is a requirement for
any assay to be positive in ,5% of a control population.28 30
When the assay is performed at its optimum, it achieves a
sensitivity of 80% and a specificity of 95%. It is considerably
affected by the pretest probability. The overall prevalence of
rheumatoid arthritis in the population is 0.8%. Using an assay
that complies with the American Rheumatism Association
guidelines, this gives a positive predictive value of RhF of 10%;
it is therefore unsuitable for population screening.27 28
In instances where an inflammatory arthopathy is present
(raised ESR or CRP, joint swelling or damage), the positive
predictive value rises to .75% and the negative predictive value
is around 90%, making the test a useful diagnostic aid,
providing an appropriate assay method is used.27 28
The prevalence of RhF increases with age, and 10–20% of
people .65 years will be seropositive.27 28
The titre of the RhF is, in addition, an important predictor of
severity of rheumatoid arthritis, and high titres (.100 IU) are
associated with the development of radiographic erosions and
extra-articular manifestations.29 31–33
Other antibody subtypes (IgG and IgA) have not found a
place in the routine investigation of rheumatoid arthritis. There
are reports of more severe disease associated with the presence
of IgA RhF.27 34
RhF is useful in the diagnosis of rheumatoid arthritis when
inflammatory arthropathy is present but cannot be used as a
screening test. It provides prognostic information on the
severity of the disease and the likelihood of erosions and
extra-articular manifestations. Other subtypes have not proved
useful in managing the disease, but further studies are
required.
Should I repeat RhF measurement to obtain information
in the monitoring of rheumatoid disease?
We do not recommend use of RhF in monitoring
rheumatoid disease.
The measurement of RhF varies depending on the assay used.
The only quantitative assays statistically consistent enough for
monitoring purposes would be nephelometry and ELISA
methods.
However, no studies are convincing enough to show that
even using a precise assay the level of the RhF has more than a
weak association with the disease process.35–37
There is a slow change in RhF in association with disease-
modifying drugs such as penicillamine. This drop, although
important, does not correlate with changes in ESR or joint
score.35–37
Possible reasons for this poor correlation are:
N the circulating level of RhF does not reflect the tissue or joint
level
N the RhF is a byproduct of a disease process rather than a
causative agent. Newer assays including cyclic citrinullated
peptide37 suggest this may be the case
N measurement of IgM RhF does not adequately reflect the
total mass of complexes as it does not include contributions
from IgG and IgA.
There has been a report of the loss of RhF before the
development of lymphoma in patients with Sjogren’s syn-
drome, but further studies are required before its use can be
recommended.38
RhF therefore adds no information in the monitoring of
rheumatoid arthritis, and alternative assays such CRP as a
marker of inflammation should be used if a marker of disease
activity is needed.
When should I test for HLA B27 in a patient with back
pain?
We recommend that:
N B27 testing not be requested in primary care
N criteria for specialist advice/referral should rather be based
on the presence of inflammatory back pain defined as >3 of
the following features:
– back pain persisting for >3 months
– back stiffness, especially in the morning, lasting for at
least 30 min
– age of onset ,40 years
– insidious onset of back pain
– back pain improved by exercise.
The human leucocyte transplantation antigen B27 is asso-
ciated with ankylosing spondylosis and is present in about 90%
of white and 50% of black patients with ankylosing spondylosis
and other spondyloarthritides (SpA), many of which may
represent early forms of ankylosing spondylosis.39 40 However, it
is insensitive as a test alone (20% sensitivity), as many people
with the B27 antigen do not develop ankylosing spondylosis
and B27 has a high prevalence in many populations.
Although radiological evidence of sacroileitis is reported to be
the most specific and consistent finding in ankylosing
spondylosis, it may be absent in early disease and in SpA.41
Several recommendations for B27 testing suggest restricting
its use to atypical patients with symptoms of inflammatory
back pain associated with radiological sacroileitis, or in patients
without radiological sacroileitis otherwise likely to have
ankylosing spondylosis (eg, uveitis and back pain).42–45
The presence of inflammatory back pain used by the
European Spondyloarthropathy Study Group46 and based on
Clin’s questionnaire47 can be defined by >3 of the following
features:
N back pain persisting for >3 months
N back stiffness, especially in the morning, lasting for at least
30 min48
N age of onset ,40 years
N insidious onset of back pain
N back pain improved by exercise.
A recent review of published findings for ankylosing
spondylosis and SpA found that presence of inflammatory
back pain seems to raise the average background probability of
SpA from 5% to 14% in patients with chronic back pain.49 When
combined with positive B27 measurement, the positive pre-
dictive value for SpA was found in this review to be to 54%,
rising to 90% and more if other clinical features (anterior
uveitis, enthesitis) are present. This seems to have reopened the
debate about the targeted use of B27 in clinically equivocal
situations in suitable populations.50–52
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However, the permutations of clinical scenarios and popula-
tion differences render this test of limited use in a primary care
context, particularly as the principal discriminator for SpA is
inflammatory back pain.
Patients with SpA respond to the same appropriate anti-
inflammatory and other newer specific treatments as those
with ankylosing spondylosis. There is still, however, no clear
evidence that early identification of patients with SpA,
estimated to represent potentially 5% of patients with primary
care chronic back pain,53 will lead to improved long-term
outcome, although accurate identification will help to focus
treatment.
Use of the test is further limited by the fact that pretest and
post-test probabilities also vary greatly between populations,
however, because of large differences in both the prevalence of
B27 in populations and the prevalence of B27 among patients
with spondylarthropathy.45
The test is comparatively expensive and is not suitable for use
as a screening or diagnostic test.
Testing is for HLA B27 in primary care is not currently
appropriate, and discussion with a specialist rheumatologist is
advisable if a spondyloarthropathy is suspected. B27 testing if
performed would normally form part of secondary care
assessment.54
GMS contract indicator: none.
LABORATORY INVESTIGATION OF CHRONIC
DIARRHOEA (GH, DGW, PJG)
These questions divide the investigation of chronic diarrhoea
simplistically between causes in adults and those in children.
Although a clear overlap exists, the prevalence of causes varies
both between the age groups and within individual groups.
There are so many possible causes of diarrhoea and presenting
clinical situations that it is not possible to establish a single set
of recommendations, and what emerges from the reviews
identified is the need for a detailed clinical filter to guide
further investigations. There is also no absolute boundary
between investigations that would normally be requested in a
primary and secondary care setting, and a division is offered
based on author opinion. This answer considers diarrhoea in
the context of chronic bowel disease, excluding colorectal
carcinoma, which if suspected clinically would be referred for
urgent secondary care assessment. A separate question will
examine the utility of faecal occult blood testing.
What initial screening investigations are used to
investigate chronic adult diarrhoea in primary care in
the UK?
We recommend, once chronic diarrhoea has been con-
firmed, if the cause is not clinically apparent from a
clinical filter:
N full blood count (FBC), vitamin B12, folate, urea and
electrolytes, liver function tests calcium, ferritin, ESR or
CRP and IgA endomysial antibodies, glucose (fasting) and
thyroid function
N a stool sample for microbiology investigations if recent
foreign travel was undertaken
N subsequent endoscopic investigations depending on clinical
presentation.
Chronic diarrhoea is common, affecting between 4% and 14%
of adults.55 56
The first step in investigation is to confirm that the
presentation is chronic not acute. This may be defined as the
abnormal passage of >3 loose or liquid stools/day for .4 weeks
and/or a daily stool weight of .200 g/day.57 As stool weight is
currently rarely performed and symptom reporting may vary,
considerable potential exists for overlap between functional
and organic bowel disease.
Once confirmed, a detailed history for risk factors for organic
disease and/or reported symptoms (blood or mucus in stool,
abdominal pain) will guide further investigations (organic as
opposed to functional disease, family history, previous surgery,
use of ethanol or drugs, antibiotic treatment and recent
overseas travel).
The screening tests recommended have high specificity for
organic disease in a small cohort of patients with normal stool
and colonic investigations,58 but was only 62% sensitive for
detecting disease. Normal screening tests do not therefore
exclude organic disease, nor do the existing positive and
negative symptom criteria.59–61
ESR or CRP are specific but insensitive indicators of chronic
inflammatory disease.62
FBC, urea and electrolytes, liver function, vitamin B12 and
folate, calcium and iron studies will provide evidence of
possible malabsorption.57 The presence of iron deficiency is
also a non-specific indicator of small-bowel enteropathy,
particularly celiac disease.63
The British guidelines57 recommend that routine screening
for coeliac disease (currently with IgA endomysial antibodies)
be performed in view of the high prevalence of the disease in
Western countries.
If evidence of malabsorption is found, the British guidelines
also recommend specific testing (eg, faecal elastase as a test for
pancreatic insufficiency) in view of the difficulties and
decreasing availability of 3-day faecal fat measurement, and
uncertainty as to the diagnostic utility of other primary faecal
investigations.
Systemic diseases such as thyrotoxicosis, parathyroid disease,
diabetes mellitus and adrenal disease may also be a cause of
chronic diarrhoea via a variety of mechanisms including
endocrine effects, autonomic dysfunction, bacterial overgrowth
or the use of concomitant drug treatment.64
Chronic diarrhoea due to infectious agents is rare in the
developed world, but may be considered where there has been a
history of travel to high-risk areas. Protazoan infections such as
giardiasis and amoebiasis are the most common parasitic
causes of chronic diarrhoea in travellers.
What init ial screening investigations are used to
investigate chronic childhood diarrhoea in primary care
in the UK?
We recommend:
N detailed history and careful anthropometric assessment from
historical records
N careful dietary history dealing with any anomalies
N further investigations in children not growing or acutely
unwell are usually undertaken in secondary care.
Simple investigations that might be considered if samples
can be collected and the stool samples delivered to the
laboratory within 3 h are:
N stool sample for parasites
N faecal-reducing substances
N faecal elastase (or chymotrypsin)
N blood sample (if considered appropriate) for
– FBC
– endomysial antibodies
– ferritin
– alkaline phosphatase.
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Chronic childhood diarrhoea can be defined as the passage of
>4 watery stools per day persisting for at least 2 weeks.65 66 In
most instances, the protracted diarrhoea seems to follow an
episode of acute gastroenteritis in early infancy, which has
sensitised the intestine to foreign proteins, especially milk
(secondary lactose intolerance).
A detailed clinical history and anthropometric assessment is
essential. Blood in the stool should lead to prompt referral to
secondary care to exclude chronic infections (eg, giardiasis or
underlying immunocompromise), intestinal polyps or inflam-
matory bowel disease.
Toddler diarrhoea, commonly referred to as ‘‘peas and carrot
diarrhoea’’ is the most common form after gastroenteritis in
infants. It probably extends on to childhood and is associated
with some discomfort—a variety of treatment approaches
including stress reduction showing effect. The primary feature
is that the child appears healthy and is growing normally. In
some children, a family history of irritable bowel syndrome may
be found.
A dietary history should check for excess intake of fruit
juices, squash, fizzy drinks, sugar-free gum or boiled sweets.
Concomitant respiratory disease or recurrent infections should
prompt consideration of cystic fibrosis or immunocompromise.
A history of foreign travel outside western Europe would widen
possible aetiologies.
Further investigations are normally not considered necessary
for ‘‘routine’’ acute non-severe diarrhoea, although they are
recommended in complicated cases: bloody diarrhoea, sus-
pected food poisoning, systemically ill children or recent foreign
travel.67–69 The effect of testing on outcome does not seem to
have been subjected to randomised clinical trials.
The decision to refer to secondary care will be governed by
the child’s age, growth records and severity of symptoms.65 This
guidance, therefore, is restricted to laboratory tests to identify
the most common classes of aetiology in primary care and to
assist in the referral decision. In practice, this can be
summarised by initial investigations designed to discriminate
functional diarrhoeas from food intolerances, infectious and
post-infectious diarrhoea, inflammatory colitis and malabsorp-
tion (fig 1).
Further investigation of malabsorption and the diagnosis of
enteropathies relies greatly on endoscopy and/or biopsy,65 70 71
and would therefore be expected to take place in a secondary
care setting.
Infectious or parasitic diarrhoea may be suspected from a
clinical history of foreign travel, contact with animals or contact
with infected children. Examination of fresh stool or parasites
(three consecutive days, submitted to the laboratory within
3 h) will identify three quarters of cases of giardia infestation.72
Diarrhoea is unlikely to become persistent after bacterial or
viral infection except in the situation of post-infectious
enteritis, which although less uncommon in Western popula-
tions67 makes up a large proportion of cases of infantile
enteritis.71
Children with post-infectious disaccharide intolerance
usually respond to an exclusion diet of milk and egg. The
success often involves good paediatric dietetic input and hence
referral.
Further investigation might be considered, but can equally be
performed in secondary care. Malabsorption, particularly due to
cystic fibrosis, may be screened for by measurement of faecal
elastase (or chymoptrypsin) or faecal microscopy for fat
globules on three samples, either sent freshly or frozen till
dispatch. Carbohydrate intolerance including inherited defects
in the gut endothelium, such as sucrose-isomaltase deficiency,
manifest with faecal-reducing substances, again in a fresh (or
promptly frozen) sample.
If the child is old enough and venepuncture is considered
reasonable in primary care, a sample for either anti-endomysial
antibodies (with IgA to exclude concomitant IgA deficiency) or
anti-tissue transglutamase antibodies offer a high sensitivity
and specificity for coeliac disease. Measurement of FBC, ferritin
and alkaline phosphatase offers a simple screen for evidence of
malabsorption of iron and vitamin D (although alkaline
phosphatase may require laboratory advice for interpretation
in children in the context of age and maturity status before
considering vitamin D measurement).
GMS contract indicator: none.
MUMPS AND CHICKENPOX (WI, KK)
These two questions are the first of a set of four examining
common situations of potential viral infection in primary care,
and the need or otherwise to use diagnostic laboratory testing.
In some instances, several different methods are available to
diagnose the infection. Where possible, guidance is reported on
which method is considered preferable, although diagnostic
approaches may at present vary between laboratories.
What tests should I carry out if a pregnant woman has
been in contact with chickenpox or shingles?
We recommend:
N asking for a personal history of chickenpox
N if no history is forthcoming, then send clotted blood for
varicella-zoster virus (VZV) immunity testing
N if significant contact and VZV immunoglobulin negative,
passive immunisation should be offered
Figure 1 Suggested algorithm for primary care investigation of persistent diarrhoea (adapted from Knight and Sandhu69). *, If clinically indicated; CRP, C
reactive protein; ESR, erythrocyte sedimentation rate; FBC, full blood count; FOB, faecal occult blood.
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N if a rash has already developed (specific cases are discussed
in the text).
The clinical problem is that a susceptible woman who is in
contact with chickenpox or shingles may acquire infection.
Primary VZV infection in pregnancy carries a risk of life-
threatening varicella pneumonia to the mother. This is more
common in a pregnant than in a non-pregnant woman. Risk
factors for severe lung involvement include smoking and a
more extensive rash (defined as .100 skin lesions).73 74 The
virus may also cross the placenta and infect the fetus, which
may give rise to the fetal varicella syndrome, also known as
varicella embryopathy.75 There are protean manifestations of
this, the most distinctive of which are extensive areas of skin
scarring and failure of limb bud development. The risk is of the
order of 1–2% in women with chickenpox in the first half of
pregnancy.75 Fetal damage arising through maternal varicella at
20–28 weeks gestation has been described in isolated case
reports, but is rare.76 Finally, maternal varicella occurring at the
end of pregnancy (ie, within 7 days before and after delivery)
may result in the baby acquiring neonatal varicella, which has a
considerable mortality.
Management of a pregnant woman in contact with chick-
enpox or shingles hinges on whether she has already been
infected with VZV. The simplest way to elicit this is to ask about
a history of chickenpox; if this is clearly established, she can be
reassured that there is no risk arising from her recent contact,
as second epsiodes of chickenpox are extremely unusual, and
no adverse events from them in pregnancy have yet been
described.73 If the history is unclear, the next step is to test a
serum sample for the presence of IgG to VZV. Laboratories
should be able to generate a result within 24–48 h of receiving
the sample. Most women (well over 80%) of child-bearing age
in the UK have such antibodies even if they do not recall the
episode of chickenpox,77 although this figure is lower for
women born and raised in tropical or subtropical areas.78
Antibodies detected within 10 days of contact indicate past
infection (or immunisation) and can used to provide reassur-
ance of no risk.
If the patient has no history of chickenpox, and a serum
sample is shown to be negative for VZV antibodies, then
recommended management is to offer passive immunisation
with varicella-zoster immunoglobulin (VZIG), prepared from
pooled plasma from donors with high titres of varicella
antibodies), provided the contact is significant, and within
10 days.79 Significant contact is defined as being in the same
room as someone with chickenpox for 15 min, having face-to-
face contact with someone with chickenpox (eg, a conversa-
tion) or living in the same household.79 An individual with
chickenpox or disseminated zoster is infectious for 48 h before
the onset of the rash until the lesions have crusted over. An
individual with exposed zoster (eg, ophthalmic zoster) should
be regarded as infectious from the day of onset of the rash until
crusting has occurred.79
About 50% of susceptible women given VZIG will develop
clinical varicella, although the disease may be attenuated and a
further 25% will develop subclinical infection.79 Patients who
have received VZIG on a previous occasion should be retested
for VZV antibodies in the event of another relevant exposure to
chickenpox or shingles. There is also evidence that VZIG
reduces the risk of transplacental transmission of VZV, which
will thereby reduce the risk of embryopathy.74 These women
should be advised of the potential risks of fetal varicella arising
from their infection. Serial ultrasound monitoring of the fetus
may allow identification of the abnormalities associated with
varicella embryopathy at a time when it is possible to offer
termination.
VZIG is of no benefit if a pregnant woman presents with
chickenpox. The Royal College of Obstetricians and
Gynaecologists guidelines state that in this setting, oral
aciclovir should be recommended to women .20 weeks of
gestation on the first day of the rash, with informed consent,
whereas for women ,20 weeks gestation, aciclovir should be
offered.73 If maternal chickenpox develops within 7 days of
delivery, the neonate should be given VZIG and the use of
prophylactic aciclovir considered, to reduce the risk of life-
threatening neonatal varicella.79
GMS contract indicator: none.
When should I test for mumps, and should I notify
mumps infection?
We recommend:
N testing for mumps virus infection in cases clinically
compatible with the disease
N mumps virus infection is a notifiable disease in the UK.
Mumps virus infection may present as asymptomatic
seroconversion (ie, subclinical infection) in about 30% of
infections.80
After an incubation period of 14–21 days, a prodromal illness
may occur with malaise, myalgia, low-grade fever, headache
and lasting for 1–2 days before the onset of parotitis, which
occurs in 95% of symptomatic disease, and is bilateral in 75% of
cases. Glands are swollen and tender, duct orifices red and
oedematous. Swelling lasts for 4–7 days. Submandibular and
sublingual glands are occasionally involved. Patients are
infectious from 7 days before to 9 days after the onset of
parotitis.
Complications include central nervous system involvement:
aseptic meningitis (5–10% cases, men more often than
women), meningoencephalitis (about 1 in 6000 cases), which
may cause convulsions, focal neurological signs, motor or
sensory disorders, and hearing loss, which may occur in the
absence of meningitis or encephalitis; orchitis, epididymitis,
oophoritis (said to occur in up to 40% and 5% of post-pubertal
men and women, respectively); pancreatitis (usually not
severe); and rarely, arthritis and myopericarditis.
Central nervous system manifestations may occur in the
absence of clinically evident salivary gland disease.
Infection during pregnancy may increase the risk of
spontaneous miscarriage, but a congenital mumps syndrome
has not been described.
The clinical diagnosis of mumps may be unreliable, and cases
are rare especially in populations with a low incidence. One
study in Australia reported laboratory confirmation of only 9%
of all notified mumps cases.81 The positive predictive value of
the clinical case definition was only 10%.
Mumps is a notifiable disease in the UK, and therefore all
clinically suspected cases should be reported to the local
Consultant for Communicable Disease Control. Monitoring of
infection is important in determining appropriate immunisa-
tion policies; there have been a number of outbreaks of mumps
among young adults in the UK over the past 5 years and a large
increase in notified cases.82
For reasons outlined earlier, it is therefore important to
confirm a clinical diagnosis of mumps virus infection by
sending appropriate specimens for laboratory confirmation.
Several laboratory methods exist to diagnose mumps infection.
It is possible to detect mumps IgM in saliva samples for up to
5 weeks after acute infection.83 Detection of mumps-specific
IgM in an acute serum sample, or a rising titre of mumps IgG in
paired acute or convalescent sera, can also be used to confirm
the diagnosis. Finally, a buccal or throat swab, broken off into
viral transport medium, can be used to isolate the virus or
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detect viral RNA. The virus is excreted in saliva for up to
2 weeks, and in urine for up to 3 weeks after acute infection.
In the UK, the Health Protection Agency offers oral fluid
testing for mumps IgM, which can be performed via a salivary
kit obtained from laboratories. Local practices may however
vary, and practitioners should establish the local methods in
use from their microbiology/virology services.
GMS contract indicator: none.
CONCLUSION
This review brings to a running total of 77 question and answer
sets written to provide an overview of current advice in the use
of laboratory tests in primary care. Answers to the first four
question answer sets can be found in Smellie et al.84–88 They have
all used a common search method,89 although in instances
where recent systematic reviews have been performed, the
guidance also relies heavily on the findings of these reviews.
Authors wishing to consult the UK General Medical Services
Contract and the current Quality and Outcomes Framework
guidance can find these on their respective websites.90 91
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